United Therapeutics (UTHR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Thome from TD Cowen maintained a Buy rating on the stock and has a $400.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Thome has given his Buy rating due to a combination of factors that highlight United Therapeutics’ strong financial performance and growth potential. The company reported first-quarter revenues that significantly exceeded market expectations, driven by robust sales of key products like Tyvaso, Remodulin, and Orenitram. This performance underscores the continued patient demand and successful product referrals, which are crucial for sustaining revenue growth.
Moreover, United Therapeutics’ management is optimistic about achieving double-digit revenue growth in the near term, supported by their current product portfolio. The company is also exploring new market opportunities, particularly in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Additionally, potential developments in their pipeline, such as a once-daily inhaled product, further bolster the company’s growth prospects. These factors contribute to Thome’s positive outlook and Buy rating for United Therapeutics’ stock.
In another report released on April 25, Leerink Partners also reiterated a Buy rating on the stock with a $420.00 price target.